REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced that on July 24, 2024, it received an extension of 180 calendar days from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in ...

As filed with the Securities and Exchange Commission on July 22, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Lior Fhima, Chief Financial Officer 4 Oppenheimer Street Science Park Rehovot 7670104, Israel Tel: +972-3-933-3121; Fax: +972-3-5097196 PURPLE BIOTECH LTD. (Exact na ...

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage oncology therapies, particularly focusing on CM24 in combination with nivolumab and chemotherapy for treating second-line metastatic pancreatic ductal adenocarcinoma (PDAC) [1][2][3]. Group 1: Event Details - A virtual key opinion leader (KOL) event is scheduled for July 11, 2024, featuring discussions on positive interim data from the Phase 2 study of CM24 [1][2]. - The event will include a live question and answer session following the formal presentation [5]. Group 2: Clinical Data Highlights - The 2024 ASCO Annual Meeting reported data showing reduced risk of death and progression, prolonged overall survival (OS), and progression-free survival (PFS) with the CM24+nivolumab+chemotherapy combination [3]. - The combination therapy demonstrated a higher objective response rate (ORR) and disease control rate (DCR), along with decreasing CA19-9 levels [3]. Group 3: CM24 Mechanism and Development - CM24 is a humanized monoclonal antibody that blocks CEACAM1 interactions, which are involved in tumor immune evasion [3][9]. - Purple Biotech is advancing CM24 as a combination therapy in a Phase 2 study, collaborating with Bristol Myers Squibb for clinical trials [9]. Group 4: Company Overview - Purple Biotech Ltd. is focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes NT219, CM24, and IM1240 [8][9]. - The company is headquartered in Rehovot, Israel, and aims to engage both T cells and NK cells through its innovative therapeutic platforms [9].

Forward-Looking Statements and Safe Harbor Statement About Purple Biotech REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing ...

REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging ...

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. NalIRI/5FU/LV arms Data reported at the 2024 ASCO annual meeting demonstrated reduced risk of death and cancer progression, prolongation of OS and progression free survival (PFS) as well as higher objective response rate (ORR) and disease control rate (DCR) and decreasing CA19-9 levels in the CM24+Nivolumab+NalIRI/5FU/LV arm ...

New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. NalIRI/5FU/LV arms Data reported at the 2024 ASCO annual meeting demonstrated reduced risk of death and cancer progression, prolongation of OS and progression free survival (PFS) as well as higher objective response rate (ORR) and disease control rate (DCR) and decreasing CA19-9 levels in the CM24+Nivolumab+NalIRI/5FU/LV arm ...

Michael Cecchini, MD Assistant Professor of Medicine at the Yale Cancer Center, a principal investigator in this study, commented, "As a clinician, it is encouraging to see these interim data in the Nal-IRI arm suggesting the potential for improved clinical outcomes for patients with late-stage metastatic PDAC who are in dire need of new effective therapies. These patients face very limited time with their families, and the prospect of potentially lengthening their lives while delaying their disease progres ...

REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the three months ended March 31, 2024. "We look forward to presenting compelling interim Phase 2 CM24 data for the treatment of pancreatic cancer at ASCO 2024, where we were selec ...

Core Insights - Purple Biotech Ltd. reported financial results for Q1 2024, highlighting progress in clinical trials and a focus on developing therapies targeting tumor immune evasion and drug resistance [1][21]. Financial Performance - Research and Development Expenses were $3.4 million for Q1 2024, a decrease of 2.8% from $3.5 million in Q1 2023 [13]. - Sales, General and Administrative Expenses were $1 million for Q1 2024, down from $1.6 million in Q1 2023, representing a decrease of $0.6 million [13]. - Operating Loss for Q1 2024 was $4.5 million, a reduction of 11.8% compared to $5.1 million in Q1 2023 [14]. - Net Loss for Q1 2024 was $3.8 million, or $0.14 per basic and diluted ADS, compared to a net loss of $4.9 million, or $0.25 per basic and diluted ADS in Q1 2023 [15]. - As of March 31, 2024, the company had cash and cash equivalents of $10.8 million, providing a cash runway into Q1 2025 [16]. Clinical Developments - The company is set to present interim Phase 2 data for CM24 in pancreatic cancer at ASCO 2024, which may indicate reduced risk of disease progression and death [2][4]. - NT219 is progressing towards a Phase 2 trial in head and neck cancer, with positive early results presented at ESMO-TAT 2024 showing a 29% objective response rate and a 71% disease control rate [6][9]. - The tri-specific antibody platform is expected to produce promising drug candidates, with the lead asset IM1240 anticipated to be ready for Phase 1 study by early 2026 [19]. Research Highlights - The Phase 2 study of CM24 is evaluating its efficacy in combination with nivolumab and standard chemotherapy in advanced pancreatic cancer patients [5]. - NT219 has shown potential in suppressing cancer stem cells and overcoming resistance to KRAS inhibitors, with findings presented at AACR 2024 [7][9]. - A Scientific Advisory Board has been established to guide the development of NT219 in combination with cetuximab for recurrent/metastatic head and neck cancer [11].